Abstract:Background: Psoriasis is a common inflammatory skin condition that varies in severity. Most patients have limited disease amenable to topical treatment; however, poor treatment adherence limits efficacy. The purpose of this study was to assess patients’ psoriasis treatment experience, expectations, and preferences. Method: The National Psoriasis Foundation conducted a 17-question survey in March 2022 assessing psoriasis severity, bothersome signs and symptoms, current treatment modalities, frequency of topical therapy use, and vehicle preferences. Statistical analysis of the qualitative data was performed using descriptive analysis and calculations of relative frequencies. Results: Most participants self-reported moderate psoriasis (83.9%). The most common bothersome symptoms were scaly appearance (78.8%), bleeding/oozing (60%), itch (55%), and flaking (37.4%). For treatment, 72.5% of participants disclosed using oral medication, while 8% used topical treatment alone. Most participants (76%) reported using topical therapy at least once weekly. Nearly 80% of participants said they would allow 2 weeks for a medication to become effective before considering discontinuation. Participants preferred water-based creams (75.7%), followed by oil-based foam (70.8%), gel (48.7%), solution (42.8%), lotion (21.2%), non-oil-based foam (17.5%), ointment (16.5%), and spray (6.3%). The formulation attributes rated most important were application feel (55.2%), non-staining (49.9%), quick absorption (46.7%), non-sticky texture (39.7%), ease of application (28.5%), no unpleasant smell (22.4%), non-greasy (16.8%), works quickly (14.1%), absent sting or burn (10%), no adverse skin reaction (9.7%), and once daily treatment (6.8%). If participants did not like a topical treatment's formulation, most (74.7%) said they would continue to use the medication for a week before discontinuation. Conclusion: Topical treatments continue to be a mainstay of psoriasis treatment. Patients expect to see rapid improvement with topical treatment; otherwise, they report that they will discontinue treatment. The characteristics of psoriasis treatment vehicles also affect patients’ reported willingness to use treatment and may be an important consideration in treatment planning. J Drugs Dermatol. 2023;22(4): doi:10.36849/JDD.7372 Citation: Curcio A, Kontzias C, Gorodokin B, et al. Patient preferences in topical psoriasis treatment. J Drugs Dermatol. 2023;22(4):326-329. doi:10.36849/JDD.7372.

Demographics, Disease Characteristics, and Time to Effective Treatment of Patients with Psoriasis in the Ghent PsoPlus Cohort of 2021

Expert Consensus on the Treat-to-target Strategy for Psoriasis with Biological Agents in China

Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares

Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)

The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis

Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004–2022

Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry

Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis

Study Protocol of the Global Effisayil 1 Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial of Spesolimab in Patients with Generalized Pustular Psoriasis Presenting with an Acute Flare

Persistence of advanced systemic pharmacological treatment of moderate-to-severe psoriasis among bio-naïve patients-A retrospective register-based cohort study in Finland and Sweden

Characteristics of Patients With Psoriasis Treated With Various Biologics - A Danish Cohort Study

Belgian recommendations for managing psoriasis in a changing treatment landscape

Patient Preferences in Topical Psoriasis Treatment

Treatment goals in psoriasis from a patient perspective: a qualitative study

An observational study on treatment regimens and effectiveness for psoriasis in real-world settings among 407 patients in Southeast China

Evaluation of a Case Series of Patients With Generalized Pustular Psoriasis in the United States

Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey

Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry

Psoriasis healthcare during the COVID-19 pandemic: a survey among psoriasis patients (PsoCovidCare)

Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of pasi score